...
首页> 外文期刊>Cancer Cell >Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein
【24h】

Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein

机译:通过糖胺聚糖结合疟疾蛋白靶向人类癌症。

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmodiumfalciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.
机译:恶性疟原虫工程师感染了红细胞,呈递出疟疾蛋白VAR2CSA,该蛋白与胎盘中专门表达的独特类型的硫酸软骨素(CS)结合。在这里,我们表明相同的CS修饰存在于高比例的恶性细胞上,并且可以被重组VAR2CSA(rVAR2)特异性靶向。在肿瘤中,胎盘样CS链与癌症相关的蛋白聚糖(包括CD44和CSPG4)的有限组成部分相关。 rVAR2蛋白在体内定位于肿瘤,与白喉毒素融合或与半胱氨酸化合物缀合的rVAR2强烈抑制体内肿瘤细胞的生长和转移。我们的数据表明,如何利用进化上精制的寄生虫衍生蛋白来靶向常见但复杂的恶性肿瘤相关的糖胺聚糖修饰。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号